Clinical trial • Phase II • Immunology

IMEROPRUBART for Graves' disease

Phase II trial of IMEROPRUBART for Graves' disease. Randomised, placebo ("placebo is identical to imp but with no active substance.")-controlled.

Overview

Trial Therapeutic Area
Immunology
Trial Disease
Graves' disease
Trial Stage
Phase II
Drug Modality
Monoclonal antibody

Key dates

Initial CTIS Submission Date
27-06-2025
First CTIS Authorization Date
17-10-2025

Trial design

Randomised, placebo ("placebo is identical to imp but with no active substance.")-controlled Phase II trial in Czechia, Latvia, Netherlands and others.

Randomised
Yes
Comparator
Placebo ("Placebo is identical to IMP but with no active substance.")
Target Sample Size
58
Trial Duration For Participant
182

Eligibility

Recruits 58 No vulnerable populations selected. Participants must be adults (aged ≥ 18 years) able to understand the trial requirements and provide written informed consent; caregiver/supporting-person documents and consent aids are provided where applicable..

Vulnerable Population
No vulnerable populations selected. Participants must be adults (aged ≥ 18 years) able to understand the trial requirements and provide written informed consent; caregiver/supporting-person documents and consent aids are provided where applicable.

Inclusion criteria

  • {"criterion_text":"- Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures"}
  • {"criterion_text":"- Male or female participants aged ≥ 18 years"}
  • {"criterion_text":"- Participants with diagnosis of GD who are hyperthyroid despite ATD treatment"}

Exclusion criteria

  • {"criterion_text":"- Have previously been successfully treated with RAI therapy or have undergone total thyroidectomy."}
  • {"criterion_text":"- Have an autoimmune disease other than GD requiring treatment that, in the Investigator’s judgment, puts the participant at undue risk"}
  • {"criterion_text":"- Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Proportion of participants who are euthyroid and off ATD at Week 26","definition_or_measurement_approach":"Assessed at Week 26 by thyroid function and treatment status (evaluated using T3 (Total T3 or FT3), FT4, TSH and ATD dose/status as per main objective)."}

Secondary endpoints

  • {"endpoint_text":"- Proportion of participants who have T3 (Total T3 or FT3) and FT4 ≤ ULN and are off ATD at Week 26","definition_or_measurement_approach":"Laboratory measurements of T3 (Total T3 or FT3) and FT4 compared to ULN at Week 26 and ATD treatment status (off ATD)."}
  • {"endpoint_text":"- Proportion of participants who are euthyroid, off ATD, and seronegative at Week 26","definition_or_measurement_approach":"Euthyroid status plus off ATD at Week 26 and seronegativity (antibody status) as measured by relevant serology assays at Week 26."}
  • {"endpoint_text":"- Proportion of participants who are euthyroid and off ATD at Week 26","definition_or_measurement_approach":"Same as primary: assessed by thyroid function tests and ATD status at Week 26."}
  • {"endpoint_text":"- Proportion of participants who have T3 (Total T3 or FT3) and FT4 ≤ ULN and are off ATD at Week 26","definition_or_measurement_approach":"Laboratory assessment of T3 (Total T3 or FT3) and FT4 relative to ULN and ATD cessation at Week 26."}
  • {"endpoint_text":"- Proportion of participants who are euthyroid, off ATD, and seronegative at Week 26","definition_or_measurement_approach":"Euthyroid by laboratory testing, off ATD at Week 26, and seronegative by antibody testing at Week 26."}
  • {"endpoint_text":"- Proportion of participants who have T3 (Total T3 or FT3) and FT4 ≤ ULN at Week 4 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline","definition_or_measurement_approach":"Among participants with elevated baseline T3 and/or FT4, proportion achieving T3 and FT4 ≤ ULN at Week 4 by laboratory testing."}
  • {"endpoint_text":"- Proportion of participants who have T3 (Total T3 or FT3) and FT4 ≤ ULN at Week 2 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline","definition_or_measurement_approach":"Among participants with elevated baseline T3 and/or FT4, proportion achieving T3 and FT4 ≤ ULN at Week 2 by laboratory testing."}
  • {"endpoint_text":"- Proportion of participants who have T3 (Total T3 or FT3) and FT4 ≤ ULN at Week 4 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline","definition_or_measurement_approach":"Duplicate entry: as above, Week 4 assessment of T3 and FT4 relative to ULN in those elevated at baseline."}
  • {"endpoint_text":"- Proportion of participants who have T3 (Total T3 or FT3) and FT4 ≤ ULN at Week 2 in participants who have T3 (Total T3 or FT3) and/or FT4 > ULN at baseline","definition_or_measurement_approach":"Duplicate entry: as above, Week 2 assessment of T3 and FT4 relative to ULN in those elevated at baseline."}

Recruitment

Digital Remote Recruitment
Yes
Planned Sample Size
58
Recruitment Window Months
17
Consent Approach
Written informed consent is required from each participant (participants are adults aged ≥ 18 years). Participant information sheets and consent forms (L1_SIS and ICF_Main and related documents) are provided; there are specific pregnancy and caregiver consent documents (L1_SIS and ICF_Pregnancy, L1_SIS and ICF_Caregiver) and consent aids. Consent materials are available in multiple languages (documents indicate availability in English, German, Spanish, Greek, Italian, Latvian, Latvian-Russian, Polish, Bulgarian, Czech, Dutch and others).

Methods

  • Physician referral letters (documents: K2_Physician Referral Letter) targeting physicians for patient referral
  • Posters and printed patient brochures (K2_Recruitment material_Poster; K2_Recruitment material_Patient Brochure) for clinic/hospital display and patient distribution
  • Online digital recruitment: banner ads and recruitment animation (K2_Recruitment material_Recruitment_Banner Ads; Recruitment Animation) targeted at patients via digital channels
  • Study guides and patient brochures (K2_Recruitment material_Study Guide) provided to potential participants
  • Pre-screening services provided by third party (Clariness GmbH) - pre-screening of potential participants
  • Physician and site outreach and site training activities (Icon Clinical Research Limited duties include Site Training)
  • Patient navigator and patient reimbursement support (documents and third-party duties referenced; patient reimbursement services provided by Scout Clinical and others)
  • Localized and translated recruitment materials and outreach in multiple countries/languages (documents for LV, IT, GR, EN, ES, DE, CZ, BG, PL, NL, LV-RU etc.)

Geography

Total Number Of Sites
69
Total Number Of Participants
158

Czechia

Earliest CTIS Part Ii Submission Date
18-09-2025
Latest Decision Or Authorization Date
20-10-2025
Processing Time Days
32
Number Of Sites
4
Number Of Participants
8

Sites

Site Name
Endokrinologie Klanovice s.r.o.
Contact Person Name
Markéta Weichetová
Contact Person Email
m.weichetova@post.cz
Site Name
Edumed s.r.o.
Department Name
Private Practice
Contact Person Name
Alica Veselá
Contact Person Email
Alica.vesela@edu-med.cz
Site Name
ResTrial s.r.o.
Department Name
Klinika ResTrial
Contact Person Name
Emília Malicherová
Site Name
Milan Kvapil s.r.o.
Department Name
Diabetologická ambulance
Contact Person Name
František Loos
Contact Person Email
frankyloos@gmail.com

Latvia

Earliest CTIS Part Ii Submission Date
22-09-2025
Latest Decision Or Authorization Date
20-10-2025
Processing Time Days
28
Number Of Sites
6
Number Of Participants
15

Sites

Site Name
Pauls Stradins Clinical University Hospital
Department Name
Centre of Endocrinology
Contact Person Name
Kristine Geldnere
Contact Person Email
kristineab@inbox.lv
Site Name
Veselibas un socialas aprupes klinika APS SIA
Department Name
Endocrinology
Contact Person Name
Lelde Krüzmane
Contact Person Email
lelde.kruzmane@gmail.com
Site Name
Riga East University Hospital
Department Name
Clinical Centre "Bikernieki", Ophthalmology clinic
Contact Person Name
Kristine Baumane
Contact Person Email
baumanek@ml.lv
Site Name
Siguldas Slimnica
Department Name
Outpatient Department
Contact Person Name
Renate Helda
Contact Person Email
slimnica@siguldasslimnica.lv
Site Name
Daces Teterovskas arsta prakse endokrinologija SIA
Contact Person Name
Dace Teterovska
Contact Person Email
dace.fonds@inbox.lv
Site Name
Ziemelkurzemes regionala slimnica SIA
Department Name
Ophthalmology
Contact Person Name
Kaspars Ozols
Contact Person Email
mr.kaspars.ozols@gmail.com

Netherlands

Earliest CTIS Part Ii Submission Date
03-10-2025
Latest Decision Or Authorization Date
20-10-2025
Processing Time Days
17
Number Of Sites
4
Number Of Participants
7

Sites

Site Name
Albert Schweitzer Ziekenhuis
Department Name
Internal Medicine
Contact Person Name
Simone Cornelia Christina Hartong
Contact Person Email
s.c.c.hartong@asz.nl
Site Name
Maasstad Ziekenhuis Stichting
Department Name
Internal Medicine
Contact Person Name
Charlotte van Noord
Contact Person Email
noordc@maasstadziekenhuis.nl
Site Name
Sint Franciscus Vlietland Groep Stichting
Department Name
Internal Medicine
Contact Person Name
Kim Van Der Weerd
Contact Person Email
k.weerd@franciscus.nl
Site Name
Ikazia Ziekenhuis
Department Name
Internal medicine
Contact Person Name
Carolien Beukhof
Contact Person Email
c.beukhof@ikazia.nl

Italy

Earliest CTIS Part Ii Submission Date
16-09-2025
Latest Decision Or Authorization Date
20-10-2025
Processing Time Days
34
Number Of Sites
16
Number Of Participants
54

Sites

Site Name
Azienda Ospedaliera Ordine Mauriziano Di Torino
Department Name
SC Endocrinologia
Contact Person Name
Maurillo Deandrea
Contact Person Email
mdeandrea@mauriziano.it
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
Endocrinologia
Contact Person Name
Alfredo Pontecorvi
Contact Person Email
alfredo.pontecorvi@unicatt.it
Site Name
Azienda Ospedaliera Di Rilievo Nazionale Antonio Cardarelli
Department Name
UOC Endocrinologia
Contact Person Name
Francesco Scavuzzo
Site Name
Hospital Santa Maria Della Misericordia
Department Name
Medicine and Surgery
Contact Person Name
Efisio Puxeddu
Contact Person Email
efisio.puxeddu@unipg.it
Site Name
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Department Name
PROMISE / DAI Medico / UOC Malattie Endocrine, del ricambio e della nutrizione
Contact Person Name
Giorgio Arnaldi
Site Name
Ente Ecclesiastico Ospedale Generale Regionale Miulli
Department Name
Division of Endocrinology and Metabolic Diseases
Contact Person Name
Sebastio Perrini
Contact Person Email
s.perrini@lum.it
Site Name
Azienda Sanitaria Universitaria Friuli Centrale
Department Name
Oncology Area Department
Contact Person Name
Jacopo Manso
Site Name
Azienda Ospedaliera Santa Croce E Carle
Department Name
Endocrinology
Contact Person Name
Federico Arecco
Contact Person Email
arecco.f@ospedale.cuneo.it
Site Name
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
Department Name
SC Malattie Endocrine-Diabetologia
Contact Person Name
Silvia Ippolito
Contact Person Email
sippolito@asst-pg23.it
Site Name
Ospedale San Raffaele S.r.l.
Department Name
Endocrinology Department
Contact Person Name
Andrea Giustina
Contact Person Email
Giustina.andrea@hsr.it
Site Name
Universita Humanitas
Department Name
Department of Biomedical Sciences
Contact Person Name
Andrea Gerardo Antonio Lania
Contact Person Email
Andrea.lania@humanitas.it
Site Name
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
Department Name
Dipartimento di Medicinina Generale e Specilistica
Contact Person Name
Gianluca Aimaretti
Contact Person Email
Gianluca.aimaretti@unito.it
Site Name
Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon
Department Name
Osteo-metabolic and Thyroid Disorders
Contact Person Name
Andrea Palermo
Contact Person Email
a.palermo@unicampus.it
Site Name
Azienda Unita' Sanitaria Locale Toscana Nord Ovest
Department Name
U.O. Aziendale di Endocrinologia
Contact Person Name
Daniele Barbaro
Site Name
Azienda Ospedaliero-Universitaria Policlinico Umberto I
Department Name
Department of Experimental Medicine, Sapienza University of Rome
Contact Person Name
Elisa Giannetta
Contact Person Email
Elisa.giannetta@uniroma1.it
Site Name
Istituti Clinici Scientifici Maugeri S.p.A.
Department Name
Unit of Endocrinology and Metabolic Diseases
Contact Person Name
Mario Rotondi
Contact Person Email
Mario.rotondi@icsmaugeri.it

Poland

Earliest CTIS Part Ii Submission Date
17-09-2025
Latest Decision Or Authorization Date
21-10-2025
Processing Time Days
34
Number Of Sites
13
Number Of Participants
24

Sites

Site Name
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Kielcach
Department Name
Klinika Endokrynologii
Contact Person Name
Aldona Kowalska
Site Name
Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.
Contact Person Name
Wojciech Matuszewski
Site Name
Med Polonia Sp. z o.o.
Department Name
Dział badań klinicznych
Contact Person Name
Grzegorz Konieczny
Contact Person Email
gkonieczny78@gmail.com
Site Name
Uniwersytecki Szpital Kliniczny W Bialymstoku
Department Name
Klinika Endokrynologii, Diabetologii i Chorób Wewnętrznych
Contact Person Name
Katarzyna Siewko
Contact Person Email
katarzyna.siewko@umb.edu.pl
Site Name
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
Department Name
Cetrum Diabetologiczne Kiliniki Chorób Wewnętrznych, Endokrynologii i Diabetologii
Contact Person Name
Edward Franek
Contact Person Email
edward.franek@pimmswia.gov.pl
Site Name
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
Department Name
Klinika Endokrynologii
Contact Person Name
Marek Bolanowski
Contact Person Email
marek.bolanowski@umw.edu.pl
Site Name
Trialmed Sp. z o.o.
Department Name
Clinical Trials
Contact Person Name
Iwona Kaczor- Zabój
Contact Person Email
ikz@trialmed.pl
Site Name
Uniwersytecki Szpital Kliniczny Nr 1 Im. Prof. Tadeusza Sokolowskiego Pum W Szczecinie
Department Name
Centrum Wsparcia Badań Klinicznych Pomorskiego Uniwersytetu Medycznego
Contact Person Name
Anhelli Syrenicz
Contact Person Email
cwbk@pum.edu.pl
Site Name
Centrum Medyczne Intercor Sp. z o.o.
Contact Person Name
Roman Junik
Contact Person Email
intercor@farmepo.com
Site Name
Diab Serwis Popenda Sp. j.
Contact Person Name
Grażyna Popenda
Site Name
Reumed Sp. z o.o.
Department Name
Poradnia endokrynologiczna i diabetologiczna
Contact Person Name
Agnieszka Zwolak
Contact Person Email
zwolakag@wp.pl
Site Name
Clinicly Sp. z o.o.
Department Name
Clinicly Sp. z o.o. Centrum Medyczne Clinicly
Contact Person Name
Agata Bronisz
Contact Person Email
agata.bronisz.opole@gmail.com

Bulgaria

Earliest CTIS Part Ii Submission Date
10-09-2025
Latest Decision Or Authorization Date
22-10-2025
Processing Time Days
42
Number Of Sites
16
Number Of Participants
22

Sites

Site Name
Medical Center Berbatov Ltd.
Contact Person Name
Dimitar Berbatov
Contact Person Email
dr.berbatov@gmail.com
Site Name
Multiprofile Hospital For Active Treatment Hadji Dimitar OOD
Department Name
Department of Endocrinology and Metabolic Diseases
Contact Person Name
Ghassan Farah
Contact Person Email
gasan_farah@mail.bg
Site Name
Medical Center Smolyan Klinikal Research Ltd.
Contact Person Name
Emiliya Apostolova
Contact Person Email
vitamed@abv.bg
Site Name
Diagnostic Consultative Center Equita OOD
Contact Person Name
Neli Klyuchkova
Contact Person Email
klychkova@gmail.com
Site Name
Medical Center Viva Phoenix OOD
Contact Person Name
Kaloyan Velkov
Contact Person Email
kaloyanvelkov@gmail.com
Site Name
Medical Centre Pratia Clinic EOOD
Contact Person Name
Artin Magardichyan
Site Name
Alexandrovska University Hospital
Department Name
Clinic of Endocrinology and Metabolic Diseases
Contact Person Name
Zdravko Kamenov
Contact Person Email
zkamenov@hotmail.com
Site Name
University Specialized Hospital For Active Treatment In Endocrinology Akad. Iv. Penchev EAD
Department Name
Third Clinic of Endocrinology and Metabolic Diseases
Contact Person Name
Roussanka Kovatcheva
Contact Person Email
roussanka_kov@yahoo.com
Site Name
Kalimat Medical Center Ltd.
Contact Person Name
Mariana Yoncheva-Mihaylova
Contact Person Email
mdyoncheva@gmail.com
Site Name
Medcenter Nova Clinic Ltd.
Contact Person Name
Gergana Marinova
Contact Person Email
gergana_tosheva@abv.bg
Site Name
Multiprofile Hospital For Active Treatment Knyaginya Klementina Sofia EAD
Department Name
Department of Endocrinology and Metabolic Diseases
Contact Person Name
Ivaylo Lefterov
Contact Person Email
ilefterov@abv.bg
Site Name
University Multiprofile Hospital For Active Treatment Sofiamed OOD
Department Name
Clinic of Endocrinology and Metabolic Diseases
Contact Person Name
Anna-Maria Borissova Ivanova
Contact Person Email
anmarbor@abv.bg
Site Name
University Multiprofile Hospital For Active Treatment Pulmed Ltd.
Contact Person Name
Mitko Mitkov
Contact Person Email
mitko_mitkov@yahoo.com
Site Name
University Multiprofile Hospital For Active Treatment Kaspela EOOD
Department Name
Clinic of Endocrinology and Metabolic Diseases
Contact Person Name
Boyan Nonchev
Contact Person Email
nonchev_md@abv.bg
Site Name
Medical Center Berbatov Ltd. (additional site entries exist in listing)
Contact Person Name
Additional contacts available in source

Germany

Earliest CTIS Part Ii Submission Date
22-09-2025
Latest Decision Or Authorization Date
17-10-2025
Processing Time Days
25
Number Of Sites
2
Number Of Participants
10

Sites

Site Name
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Department Name
Department of Medicine I
Contact Person Name
George Kahaly
Site Name
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Department Name
Department of Medicine III, Devision of Endocrinology, Diabetes and Bone deseases
Contact Person Name
Lorenz Christian Hofbauer

Spain

Earliest CTIS Part Ii Submission Date
26-08-2025
Latest Decision Or Authorization Date
20-10-2025
Processing Time Days
55
Number Of Sites
4
Number Of Participants
10

Sites

Site Name
Hospital Universitario De La Princesa
Department Name
Endocrinology
Contact Person Name
Monica Marazuela
Site Name
Hospital Clinico San Carlos
Department Name
Endocrinology
Contact Person Name
Maria del Carmen Montañez Zorilla
Site Name
Hospital Universitario Virgen De La Macarena
Department Name
Ophthalmology
Contact Person Name
Antonio Garrido
Contact Person Email
gaherfamily@hotmail.com
Site Name
Hospital Germans Trias I Pujol
Department Name
Endocrinology
Contact Person Name
Federico Vazquez

Greece

Earliest CTIS Part Ii Submission Date
17-07-2025
Latest Decision Or Authorization Date
21-10-2025
Processing Time Days
96
Number Of Sites
4
Number Of Participants
8

Sites

Site Name
Alexandra Hospital
Department Name
Endocrine Department and Diabetical Center
Contact Person Name
Vasiliki Vasileiou
Contact Person Email
Vasvasendo@gmail.com
Site Name
Laiko General Hospital Of Athens
Department Name
1st department of internal medecine, Endocrinology Unit
Contact Person Name
Anna Angelousi
Contact Person Email
a.angelousi@gmail.com
Site Name
Evaggelismos Hospital
Department Name
Department of Endocrinology "D.IKKOS"
Contact Person Name
Marinella Tzanela
Contact Person Email
endo.evangelismos@gmail.com
Site Name
Ippokratio General Hospital Of Thessaloniki
Department Name
Department of Endocrinology, Diabetes and Metabolism
Contact Person Name
Fotini Adamidou
Contact Person Email
Fotini.adamidou@gmail.com

Sponsor

Primary sponsor

Full Name
Immunovant Sciences GmbH
Organisation Type
Pharmaceutical company
Country Of Registered Address
Switzerland

Contract research organisations

Name
Icon Clinical Research Limited
Responsibilities
Site Training, HHC, Patient Reimbursement, Equipment
Name
PRA Hellas CRO A.E.
Responsibilities
code:1; code:5
Name
Syneos Health Clinique Inc.
Responsibilities
code:4

Third parties

  • {"country":"United States","full_name":"Avance Biosciences Inc.","duties_or_roles":"code:4","organisation_type":"Pharmaceutical company"}
  • {"country":"Germany","full_name":"Clariness GmbH","duties_or_roles":"Pre-screening","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"France","full_name":"Voisin Consulting Life Sciences","duties_or_roles":"code:12","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Scout Clinical","duties_or_roles":"Patient reimbursement services","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"Netherlands","full_name":"Pharmaceutical Research Associates Group B.V.","duties_or_roles":"code:4","organisation_type":"Pharmaceutical company"}
  • {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"Site Training, HHC, Patient Reimbursement, Equipment; code:5","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Mayo Collaborative Services LLC","duties_or_roles":"code:4","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"Suvoda LLC","duties_or_roles":"code:3","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"Catalent Cts (Edinburgh) Limited","duties_or_roles":"code:14","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Catalent Pharma Solutions LLC","duties_or_roles":"code:14","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Avantor Inc.","duties_or_roles":"Long-term storage","organisation_type":"Pharmaceutical company"}
  • {"country":"Netherlands","full_name":"Certe Medische Diagnostiek en Advies Stichting","duties_or_roles":"code:4","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"Arup Laboratories Inc.","duties_or_roles":"code:4","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"Primevigilance USA Inc.","duties_or_roles":"code:8","organisation_type":"Pharmaceutical company"}
  • {"country":"Greece","full_name":"PRA Hellas CRO A.E.","duties_or_roles":"code:1; code:5","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Clinical Ink Inc.","duties_or_roles":"e-diary; code:7","organisation_type":"Pharmaceutical company"}
  • {"country":"Canada","full_name":"Syneos Health Clinique Inc.","duties_or_roles":"code:4","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
IMVT-1402
Active Substance
IMEROPRUBART
Modality
Monoclonal antibody
Routes Of Administration
Subcutaneous
Route
Subcutaneous
Maximum Dose
600 mg (max daily dose amount indicated as 600 mg); max total dose amount 15600 mg
Investigational Product Name
Placebo is identical to IMP but with no active substance.
Modality
Other

Related trials

Other published trials that may interest you.